Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Dr. Chak on Challenges With Screening For Esophageal Cancer

January 21st 2016

Amitabh Chak, MD, professor of Medicine, Gastroenterology, Case Western Reserve University School of Medicine, discusses challenges with screening patients for Barrett's esophagus and esophageal cancer.

New Neoadjuvant Regimen Shows Similar Efficacy, Less Toxicity in Rectal Cancer

January 19th 2016

Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy improved overall survival (OS) and was associated with fewer adverse events compared with standard chemoradiation for patients with locally advanced rectal cancer.

Everolimus Emerges as New Standard of Care for GI NETs

January 19th 2016

Everolimus reduced the risk of disease progression by at least 40% in patients with either gastrointestinal neuroendocrine tumors or NETs of unknown primary origin.

Results for Lu-Dotatate in Patients With Midgut NETs Continue to Impress

January 19th 2016

For patients with advanced midgut neuroendocrine tumors, the peptide receptor radionuclide therapy Lu-Dotatate continues to confer a major therapeutic benefit, reducing the risk of disease progression or death by 79% and signaling an improvement in overall survival as well.

Multitargeted Drug Slows CRC as Third-Line Therapy

January 21st 2015

Treatment with a multitargeted tyrosine kinase inhibitor led to a small but statistically significant improvement in progression-free survival (PFS) in patients with advanced, previously treated metastatic colorectal cancer.

Dr. Muro on Pembrolizumab for Gastric Cancer

January 19th 2015

Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment if several types of cancer.

Dr. Laura Dawson on HCC Challenges

January 19th 2015

Laura Dawson, MD, Princess Margaret Hospital, University of Toronto, talks about the challenges in treating hepatocellular carcinoma (HCC).

Monocyte-Targeting Agent Active in Locally Advanced Pancreatic Cancer

January 18th 2015

Almost half of patients with borderline resectable or locally advanced pancreatic cancer had objective responses to treatment with an investigational chemokine receptor antagonist.

Lanreotide Effective in Pancreatic NET Subgroup

January 17th 2015

Lanreotide improved progression-free survival and resulted in more disease control compared with an observation strategy among patients with pancreatic neuroendocrine tumors.

Ramucirumab Improves Survival in HCC Subgroup

January 17th 2015

An analysis of patients with advanced hepatocellular carcinoma and elevated Î±-fetoprotein who received second-line ramucirumab showed a significant improvement in overall survival.

Expanded NAPOLI-1 Analysis Further Characterizes MM-398 Benefit in Metastatic Pancreatic Cancer

January 17th 2015

Expanded analysis of the NAPOLI-1 trial's per-protocol population continues to support the benefit of adding the nanoliposomal encapsulation of irinotecan MM-398 to 5-fluorouracil plus leucovorin for the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine.

Polymorphisms May Offer Clues to Treatment Outcomes in HCC

January 17th 2015

Two polymorphisms of a vasodilatory enzyme had significant associations with improved survival in liver cancer treated with an inhibitor of vascular endothelial growth factor receptor (VEGFR), data from a retrospective study reported at the 2015 Gastrointestinal Cancers Symposium showed.

Dr. Wang-Gillam on PF-04136309 Plus FOLFIRINOX in Pancreatic Adenocarcinoma

January 17th 2015

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a combination treatment of PF-04136309 with FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma (PC).

Dr. Manish Shah on Onartuzumab for Gastroesophageal Adenocarcinoma

January 16th 2015

Manish A. Shah, MD, talks about a recent phase II study of mFOLFOX paired with the MET inhibitor onartuzumab for the treatment of metastatic, HER2-negative gastroesophageal adenocarcinoma (GEC).

Adjusted Nab-Paclitaxel/Gemcitabine Regimen Less Toxic in Pancreatic Cancer

January 16th 2015

Changing the administration schedule for gemcitabine plus nab-paclitaxel from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer.

Dr. Kunz on the Impact of Lanreotide's Approval for Neuroendocrine Tumors

January 16th 2015

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide.

Dr. Alexandria Phan on a CLARINET Study Subgroup Analysis

January 16th 2015

The CLARINET study led to the approval of lanreotide (Somatuline Depot) for the treatment of patients with advanced unresectable, metastatic gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs.)

MET Inhibition Shows Some Promise in Advanced Gastroesophageal Cancer

January 16th 2015

Patients with advanced, MET-amplified gastroesophageal cancer had a high likelihood of response to an investigational MET inhibitor, results from a preliminary, dose-escalation trial suggested.

Updated KEYNOTE-012 Shows Activity for Pembrolizumab in Gastric Cancer

January 15th 2015

Among patients with metastatic gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab, the agent showed promising antitumor activity and a manageable toxicity profile.

Dr. Cremolini on Frontline FOLFOXIRI Plus Bevacizumab in mCRC

January 15th 2015

Chiara Cremolini, MD, discusses findings from the phase III TRIBE trial that combined FOLFOXIRI with bevacizumab as a frontline treatment for patients with metastatic colorectal cancer.